RPS6KA4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sunitinib (SCHEMBL8081)	1.00	2/20
Sunitinib (SCHEMBL8082)	1.00	2/20
Linifanib (SCHEMBL93804)	1.00	2/20
Sunitinib (SCHEMBL18648)	0.92	2/20
Sunitinib (SCHEMBL55459)	0.84	2/20
SCHEMBL232936	0.79	2/20
SCHEMBL233874	0.79	2/20
SCHEMBL143584	0.78	2/20
SCHEMBL143543	0.77	2/20
SCHEMBL143185	0.75	2/20
SCHEMBL144887	0.74	2/20
SCHEMBL144383	0.74	2/20
SCHEMBL139873	0.72	2/20
SCHEMBL143316	0.71	2/20
SCHEMBL144905	0.71	2/20
SCHEMBL145888	0.71	2/20
SCHEMBL142711	0.70	2/20
SCHEMBL145306	0.69	2/20
SCHEMBL143624	0.68	2/20
SCHEMBL144696	0.68	2/20

Clinical trials — most relevant to RPS6KA4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle	PHASE2	NOT_YET_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Therapeutic RSK1 Targeting in Myelofibrosis	PHASE1	RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
NK Cell Deregulation in HBV Patients	nan	ACTIVE_NOT_RECRUITING
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)	nan	RECRUITING
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RPS6KA4 binder may also engage these)

Protein	Name	Similarity
Q9Z2B9	—	0.998	Q9Z2B9 →
D3ZHP7	—	0.989	D3ZHP7 →
RPS6KB2	Ribosomal protein S6 kinase beta-2	0.987	landscape →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.986	landscape →
P63318	—	0.985	P63318 →
P63319	—	0.985	P63319 →
Q4R4U2	—	0.984	Q4R4U2 →
Q63531	—	0.984	Q63531 →
O08605	—	0.983	O08605 →
Q2QX45	—	0.982	Q2QX45 →
Q3U3Q1	—	0.982	Q3U3Q1 →
Q7XSQ5	—	0.981	Q7XSQ5 →
Q9WVC6	—	0.981	Q9WVC6 →
PNCK	Calcium/calmodulin-dependent protein kinase type 1B	0.981	landscape →
Q6PFQ0	—	0.981	Q6PFQ0 →
ULK3	Serine/threonine-protein kinase ULK3	0.980	landscape →
P52785	—	0.979	P52785 →
Q6I5I8	—	0.979	Q6I5I8 →
O70126	—	0.979	O70126 →
Q8WP15	—	0.979	Q8WP15 →
P10665	—	0.977	P10665 →
P18653	—	0.977	P18653 →
P10829	—	0.977	P10829 →
Q6F3A6	—	0.977	Q6F3A6 →
Q6Z2M9	—	0.977	Q6Z2M9 →
Q95266	—	0.976	Q95266 →
Q8BW96	—	0.976	Q8BW96 →
Q5R7I7	—	0.976	Q5R7I7 →
O54784	—	0.976	O54784 →
A5A7I7	—	0.976	A5A7I7 →